This inventor holds 3 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Harm Reduction Therapeutics, Inc.. Active years: 2021-2025.
Company Filing History:
Years Active: 2021-2025
Title: John Strang: Innovator in Intranasal Pharmaceutical Dosage Forms
Introduction
John Strang is a notable inventor based in Denmark Hill, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of intranasal dosage forms. With a total of 3 patents to his name, Strang's work focuses on addressing critical health issues, such as opioid overdosing.
Latest Patents
Strang's latest patents include innovative intranasal pharmaceutical dosage forms comprising naloxone. These dosage forms are designed to contain a dosing unit with naloxone or a pharmaceutically acceptable salt thereof, in an amount equivalent to ≥0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤250 μl. This invention is particularly aimed at treating opioid overdosing and alleviating its symptoms.
Career Highlights
Strang is currently associated with Harm Reduction Therapeutics, Inc., where he continues to develop groundbreaking solutions in the pharmaceutical industry. His work is pivotal in creating effective treatments that can save lives in critical situations.
Collaborations
Some of his notable coworkers include Alexander Oksche and Stephen Harris. Their collaborative efforts contribute to the advancement of innovative healthcare solutions.
Conclusion
John Strang's contributions to the field of pharmaceuticals, particularly through his patents on intranasal dosage forms, highlight his commitment to addressing urgent health challenges. His work exemplifies the impact of innovation in improving patient care and safety.